Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem versus piperacillin-tazobactam for ceftriaxone-non-susceptible Escherichia coli or Klebsiella bloodstream infection
ACTRN12613000532707Phase 4Completed
- Sponsor
- ASID Clinical Research Network
- Start
- Feb 2014
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial in bloodstream infection (BSI) and Klebsiella infection comparing Piperacillin-tazobactam with Meropenem (2 arms). Primary endpoint: 30-day mortality. Started Feb 2014; status: completed.
02
Drugs
meropenempiperacillin + tazobactam
03
Conditions
bloodstream infection (BSI)Klebsiella infection
Beyond the preview
Go deeper on ACTRN12613000532707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000532707.